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MODIFIED DISEASE ACTIVITY SCORES THAT 
INCLUDE TWENTY-EIGHT-JOINT COUNTS
Development and Validation in a Prospective Longitudinal Study of 
Patients with Rheumatoid Arthritis
M. L. L. PREVOO, M. A. v a n ’ t  HOF, H. H. KUPER, M. A. v a n  LEEUWEN,
L. B. A. v a n  d e  PUTTE, and P. L. C. M. v a n  RIEL
Objective. The development and validation of 
Modified Disease Activity Scores (DAS) that include 
different 28-joint counts.
Methods. These scores were developed by canon­
ical discriminant analyses and validated for criterion, 
correlational, and construct validity. The influence of 
disease duration on the composition of the DAS was also 
investigated.
Results. No influence of disease duration was 
found. The Modified DAS that included 28-joint counts 
were able to discriminate between high and low disease 
activity (as indicated by clinical decisions of rheumatol­
ogists) .
Conclusion. The Modified DAS are as valid as 
disease activity scores that include more comprehensive 
joint counts.
Rheumatoid arthritis (RA) is a chronic inflam­
matory disease that is known to cause pain, disability, 
and joint destruction. Both in daily clinical practice 
and in clinical trials, many variables are recorded to 
monitor the course of the disease. Since an evaluation 
of disease activity by single variables leads to meth- 
odologic problems (1,2), several indices consisting of 
more than one variable have been developed (3-6). 
One of these indices is the Disease Activity Score
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(DAS), which was developed and validated by our 
group, in patients with recent-onset RA (5,7). The 
DAS includes 2 comprehensive joint counts, i.e., the 
Ritchie Articular Index (RAI) (8) and the total number 
of swollen joints, plus the erythrocyte sedimentation 
rate (ESR), and a general health (GH) assessment 
scored on a visual analog scale (VAS). Recent studies 
have indicated that joint counts consisting of 28 joints 
are as valid and reliable as more comprehensive joint 
counts (9,10). Herein we describe the development 
and validation of Modified DAS that include different 
28-joint counts, measuring tenderness, swelling, or 
both.
PATIENTS AND METHODS
Patients. Patients with recent-onset RA who attended 
the outpatient department at University Hospital Nijmegen 
(clinic 1) or University Hospital Groningen (clinic 2) were 
eligible for this study if they had RA according to the 
American College of Rheumatology criteria (11), had a 
disease duration o f <1 year, and had not been previously 
treated with disease-m odifying antirheumatic drugs 
(DMARDs). Between 1985 and 1994, 227 patients from clinic 
1 and 97 patients from clinic 2 took part in the study.
Parameters assessed. In both clinics, patients were 
seen by research nurses and by rheumatologists at least once 
every 3 months. The following parameters were assessed: 
pain and GH (on a VAS), morning stiffness, grip strength, 
Westergren ESR, thrombocyte count, and levels of albumin, 
hemoglobin, a r globulin, a2-gl°bulin> /3-globulin, and y- 
globulin. The following joint counts were calculated: RAI, 
total number of tender joints (53 joints), total number of 
swollen joints (TSWOLLEN [44 joints]), and 28-joint counts 
measuring tender joints (28T), swollen joints (28S), and 
joints that are both tender and swollen (28T&S) (9,12). Data 
on medication, including whether patients had stopped, 
changed, or started a DMARD or a nonsteroidal antiinflam­
matory drug, were also collected. Every 6 months, patients
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completed a Health Assessment Questionnaire (HAQ) (13). 
Plain anterior radiographs of the hands and feet were ob­
tained at least once every 3 years and were scored for the 
number of erosions and joint space narrowing by a modified 
version of Sharp’s method (14). In clinic 2, sufficient data on 
medication, GH, and HAQ were not available.
Construction of Disease Activity Scores (clinic 1). One 
of the most important aspects o f a disease activity score is 
the ability to discriminate between high and low disease 
activity. Similar to the study in which the original DAS was 
developed (5), the development of disease activity scores in 
this study was based on disease activity as indicated by the 
clinical decisions of clinic 1 rheumatologists. High disease 
activity was defined as the time at which the rheumatologist 
decided that the patient should start DMARD treatment, or 
that the DMARD being used should be changed (after a 
washout period of >  1 month for sulfasalazine or methotrex­
ate and >2 months for hydroxychloroquine, aurothioglu- 
cose, D-penicillamine, or azathioprine). Periods o f low dis­
ease activity were defined as the time the rheumatologist 
decided that DMARD treatment should be stopped because 
of remission, or periods of at least 1 year during which 
DMARD treatment was not started, or existing DMARD 
treatment was not changed. The periods of low disease 
activity were checked in the medical records for specific 
information regarding treatment decisions (noncompliance, 
refusal of therapy, etc.). In the analyses, 2 periods of high 
and 2 periods of low disease activity per patient, with a time 
period of >1 year, were randomly chosen. To obtain nor­
mality, the variables were transformed.
The original DAS was developed and validated in 
these patients during the early phase of RA; the validity in 
patients with longer disease duration has not yet been 
studied. In the present study, the development of the DAS 
was done using both patients with early disease and patients 
with established disease. In these analyses, only comprehen­
sive joint counts (RAI, total number of tender joints, and 
total number of swollen joints) were initially included, and 
principal components analysis (factor analysis) was per­
formed to group the large number of variables (complete 
data set). The newly developed DAS was obtained from 
canonical discriminant analysis and from logistic discrimi­
nant analysis. To investigate the influence of disease dura­
tion on the ability to discriminate, we divided the data 
according to 2 different disease durations: patients with short 
disease duration (<3 years) and those with longer disease 
duration (s;3 years). Principal components analyses (factor 
analyses) and canonical discriminant analyses were also 
performed according to these groupings (DASshort and 
DASlong).
In a second step, the comprehensive joint counts 
included in the newly developed DAS were replaced by 
28-joint counts. The discriminant function and canonical 
correlations of these Modified Disease Activity Scores (in 
which the 28T joint count, the 28S joint count, and the 
28T&S joint count are included) were computed by canoni­
cal discriminant analyses and by logistic discriminant analyses.
Validation of the Disease Activity Scores (clinics 1 and 
2). For the validation of the disease activity scores, data 
collected in Nijmegen (clinic 1) as well as in Groningen 
(clinic 2) were used. Since there is no single standard to
measure disease activity, several aspects of validity have to 
be evaluated (15). We chose 3 aspects: criterion validity 
(does the assessment fit with the theory about the disease; 
does the method measure the true clinical status), correla­
tional validity  (correlations with other measures that are 
supposed to measure disease activity), and construct validity  
(does the process variable lead to the ultimate result, the 
outcome).
Criterion validity was examined by means of the
correlations between the individual’s Activity
Scores and functional impairment (HAQ score and grip 
strength). For correlational validity, correlations between 
different Disease Activity Scores and with other indices of 
disease activity (3,4) were calculated, since it has been 
shown previously that the correlational validity of indices is 
substantially higher than that of single variables (7). For 
construct validity, the areas-under-the-curve of the Disease 
Activity Scores were correlated with the increase in radio- 
graphic damage. Because radiographs were obtained at least 
once every 3 years, 3 disease periods, i.e., 0-3 years, 3-6 
years, and 0-6 years, were analyzed.
RESULTS
Of the 227 patients from clinic 1, 64% were 
female, the median age at the start of the study was 55 
years, and 78% were IgM rheumatoid factor (IgM-RF) 
positive (> 10IU). Of the 97 patients from clinic 2, 66% 
were female, the median age was 51 years, and 84% 
were IgM-RF positive. For the development of Dis­
ease Activity Scores, 142 patients with 189 periods of 
high disease activity and 56 patients with 90 periods of 
low disease activity were selected.
Disease Activity Scores in early and established 
disease. Initially, principal components analysis was 
performed, resulting in 5 factors with an Eigenvalue of 
>1. The factors can be described as “ laboratory
measures,” “ semi-objective clinical scores (joint
counts), “functional status measures” (grip strength), 
“ subjective assessments by the patient” (pain, GH, 
morning stiffness), and “ /3-globulin and y-globulin.” 
To select the variables that best discriminate between 
high and low disease activity, canonical discriminant 
analysis was performed on all variables. This resulted 
in a discriminant function of 9 variables (pain, hemo­
globin, ESR, grip strength, morning stiffness, 
TSWOLLEN, RAI, /3-globulin, andas-globulin) with a 
canonical correlation of 0.81 (DAS with 9 variables). 
These 9 variables loaded on a few of the
principal components analysis. The 4 variables RAI, 
TSWOLLEN, ESR, and GH (elements of the original 
DAS) were also analyzed by canonical discriminant 
analysis. This resulted in a function with a canonical 
correlation of 0.81 (DASnew). Since canonical corre-
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Table 1. Modified Disease Activity Scores (DAS) and DASnew with assessment of general health 
(GH), developed by canonical discriminant analyses, and modified DAS without assessment of GH, 
predicted from the scores with GH by regression analyses* ________________
Canonical










0.54 x V r a i  + 0.039 x TSWOLLEN + 0.72 x InESR + 0.013 x GH 
(0.54 x V r a i  + 0.039 x TSWOLLEN + 0.72 x InESR) X  1.08 + 0.14
0.56 x V28T + 0.28 x V28S + 0.70 x InESR + 0.014 x GH 
(0.56 x V28T + 0.28 x V 28S + 0.70 x InESR) x 1.08 + 0.16
0.73 x V 28T&S + 0.76 x InESR + 0.016 x GH 
(0.73 x V28T&S + 0.76 x InESR) x 1.085 + 0.24
m m
* For the development of the scores without GH, the constant was chosen in such a way that the mean 
difference from the DAS score that includes GH was 0. RAI = Ritchie articular index; TSWOLLEN 
= total number of swollen joints (of 44); ESR = erythrocyte sedimentation rate; DAS28T+S = DAS 
with separate 28-joint counts for tender joints and swollen joints; DAS28T&S = DAS with 28-joint 
count for joints that are both tender and swollen.
lations of the DAS with 9 variables and the DASnew 
(based on 4 variables) were equal, we decided to use 
the 4 variables of the DASnew in further analyses.
To evaluate the influence of disease duration, 
principal components analyses were performed for 2 
groups: short disease duration (<3 years) and longer 
disease duration (>3 years). The 5 factors identified in 
the longer disease duration group were identical to the 
5 factors resulting from the complete data set men­
tioned above. For the short disease duration group the 
variables were grouped into 4 factors: the factor 
“functional status measures” (grip strength) was in­
cluded in the factor “ semi-objective clinical scores.” 
Because the DASnew could discriminate well, canon­
ical discriminant analyses with the 4 elements of the 
DASnew were performed for both groups and resulted 
in similar canonical correlations of 0.77 and 0.75. The 
relationships between the different Disease Activity 
Scores (original DAS, DASnew, DASshort, and 
DASlong) were evaluated by intercorrelations (Pear­
son). These were all >0.95. Therefore, it can be 
concluded that disease duration did not influence the 
composition of the Disease Activity Scores.
Modified Disease Activity Scores. In the next 
step, the 2 comprehensive joint counts were replaced 
by 28-joint counts. Discriminatory functions and the 
canonical correlations of the Modified Disease Activ­
ity Scores are presented in Table 1. The coefficients of 
the functions of the Modified DAS and the DASnew 
could not easily be compared because the variables 
were highly interrelated. The canonical correlations 
did not differ. The correlation of both Modified Dis­
ease Activity Scores with the DASnew was 0.97.
Discriminatory functions were also assessed by logis­
tic discriminant analyses. The functions resulting from 
these analyses were correlated with the functions 
resulting from canonical discriminant analyses (DAS­
new, DAS with separate 28T and 28S joint counts 
[DAS28T+S], DAS with 28T and 28S joint counts, 
DAS28T&S). All Pearson correlations between them 
were >0.99.
Validation of the Disease Activity Scores. For the 
validation of the DASnew and the Modified DAS in 
clinic 1 and clinic 2, Disease Activity Scores without 
GH (data not available from clinic 2) were predicted 
from the scores with GH (by regression). The func­
tions are presented in Table 1. The standard deviations 
of the differences between the DAS without GH 
versus the DAS with GH (accuracy) were of the 
magnitude of 0.3 (DASpoints). Table 2 shows the 
mean of the individual patients’ Pearson correlations 
between HAQ and DAS (clinic 1) or between grip 
strength and DAS (clinics 1 and 2) (criterion validity).
with HAQ or grip strength were found. Correlational 
validity was investigated by the correlations between 
DASoriginal, DASnew, DASshort, and DASlong; 
these were all >0.95. Correlations between the DAS­
new, DAS28T+S, and DAS28T&S were all >0.94. 
Correlations of all scores with the Mallya index (3) and 
the van Riel index (4) were of the magnitude of 0.80. 
For the construct validity, data on radiographic dam­
age for the disease period 0-3 years were available for 
165 patients, and data on radiographic damage for the 
period 3-6 years were available for 92 patients. Only 
the correlations for the time period 0-6 years are
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Table 2. Validation (criterion, construct) of Disease Activity Scores with Health Assessment 
Questionnaire (HAQ) scores and grip strength (mean ± SEM of individual patients’ Pearson 
correlation coefficients) and with radiographic damage (number of erosions, joint space narrowing, 
total score) (correlations of the area-under-the-curve of the Disease Activity Scores with the increase 
in radiographic damage for the time period 0-6 years)*
DASnew DAS28 T+S DAS28 T&S
HAQ
Clinic 1 (n = 131) 0.39 ± 0.038 0.38 ± 0.039 0.38 ± 0.039
Grip strength
Clinic 1 (n = 166) -0.32 ± 0.029 -0.34 ± 0.029 -0.34 ± 0.028
Clinic 2 (n = 91) -0.32 ± 0.036 -0.30 ± 0.036 -0.29 ± 0.035
Radiographic damage (clinics 1 and 2)
Number of erosions (n = 89) 0.46 0.47 0.50
Joint space narrowing (n = 89) 0.49 0.51 0.52
Total erosions + narrowing 0.49 0.51 0.53
(n = 89)
* See Table 1 for definitions.
shown in Table 2, since there was no significant 
difference between correlations for each of the 3-year 
time periods and the 6-year overall period.
DISCUSSION
Indices of disease activity such as the Disease 
Activity Scores were developed to enable evaluation 
of disease activity in individual patients as well as in 
clinical trials, with minimization of methodologic 
problems (1,2). The original DAS was developed in 
patients with early-onset RA, and includes 2 compre­
hensive joint counts. In the present study, the devel­
opment and validation of Disease Activity Scores took 
place in patients with early disease as well as more 
established disease. In addition to a Disease Activity 
Score with 9 variables, the DASnew (with the same 
elements as the original DAS) appeared to discrimi­
nate well and was preferable because of its clinical
*
simplicity. In the development of the Disease Activity 
Scores, the rheumatologist’s decisions about treat­
ment strategies were used as the outside standard for 
determining a patient’s disease activity status. This 
was a valid method since the rheumatologists were 
unaware that their decisions were part of this study, 
and although the original DAS had already been de­
veloped, the decisions of the rheumatologist could not 
be based on those scores since the ESR value (part of 
the original DAS) was not available at the time of the 
rheumatologist’s treatment decision.
The original DAS was developed in patients 
with early RA only. In the present study, an investi­
gation of the influence of disease duration on the 
ability to discriminate between high and low disease
activity was performed. The 5 factors resulting from 
the principal components analysis of the complete data 
set were comparable with the factors identified in an 
earlier study (5). The different results for the short 
disease duration group with respect to the grip 
strength variable (functional status measures) can be 
explained by the fact that grip strength reflects not 
only disease activity (process variable) but also (irre­
versible) destruction (outcome variable), which will 
develop after a lag time. The canonical correlations for 
the 2 groups with different disease durations were 
similar; therefore, no influence of disease duration on 
the structure of the Disease Activity Scores was 
observed.
In this study, the results of the canonical dis­
criminant analyses and logistic discriminant analyses 
were similar between the DASnew and the Modified 
DAS. Therefore, it can be concluded that the Modified 
DAS that include 28-joint counts discriminate just as 
well between high and low disease activity as do the 
DAS that include comprehensive joint counts. The 
Modified DAS were also validated for several features
. Tak- 
it can be
(criterion, correlational, and c
ing all these features
concluded from this study that the Modified DAS are 
as valid as the DASnew.
Since the development of the original DAS 
(which was done using discriminant analysis including 
factor values and multiple regression) differed from the 
development of the DAS in this study (done using 
canonical discriminant analysis), the functions of the 
original DAS cannot be compared with the functions
described herein. In in addition to the
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canonical discriminant analyses, logistic discriminant 
analyses were also performed; however, since these 
logistic functions correlated very highly with the ca­
nonical discriminant functions, only the functions re­
sulting from the canonical discriminant analyses were 
presented.
Another characteristic of the Disease Activity 
Scores that should be investigated is the sensitivity to 
change. This could not be evaluated in the present 
study, which used prospective data from daily clinical 
practice. According to Fuchs (16), the original DAS 
can discriminate between active drug- and placebo- 
treated patient groups. One element of the original 
DAS is the RAI, in which joints are graded for 
tenderness. Grading of tenderness was specifically 
developed to improve the sensitivity of joint counts to 
change. However, in a recent study in which several 
clinical trials were included, it was shown that reduced 
joint counts did not decrease the ability to detect 
changes over time (sensitivity to change) (10). There­
fore, it is not expected that the sensitivity of the 
Modified Disease Activity Scores would differ from 
that of the original DAS, although this must be inves­
tigated in further studies.
From the results of this longitudinal study it can 
be concluded that disease duration does not influence 
the composition of the Disease Activity Score. How­
ever, further research should be performed to deter­
mine whether the Disease Activity Scores can discrim­
inate in patients with longer disease duration than that 
of the patients included in this study. Disease Activity 
Scores including 28-joint counts can discriminate 
between high and low disease activity as well as 
Disease Activity Scores with more comprehensive 
joint counts. The validity of Modified Disease Activity 
Scores is comparable with that of Disease Activity 
Scores that include comprehensive joint counts. The 2 
Modified Disease Activity Scores (shown in Table 1) 
are similar in their ability to discriminate and their 
validity. Preference for the joint count to be included 
will lead to a choice between them.
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